Skip to content
drillr.ai
Sign up

01952.HK

Everest Medicines Limited

HKSE · Healthcare · Biotechnology · CN

HKD 31.98
−1.54%
Ask drillr

  • Aug 20, 2026, 01:46 UTC

    On August 20, 2026, Hong Kong-listed biotech stocks surged broadly, with 3D Medicines rising 55%, Everest Medicines rising 50%, CanSino Biologics rising 45%, and other biotech firms gaining sharply.

    Source:

  • Aug 19, 2026, 00:50 UTC

    Everest Medicines reported interim results for the six months ended June 2026, with revenue of RMB 1.148 billion, up 157.3% year-on-year, and net loss narrowed to RMB 5.944 million from nearly RMB 250 million a year earlier.

    Source:

  • Jul 15, 2026, 01:14 UTC

    JD Health and Everest Medicines signed a strategic cooperation agreement to jointly explore new models for full-cycle services of innovative drugs.

    Source:

  • Jun 8, 2026, 15:35 UTC

    LENZ Therapeutics granted Everest Medicines the rights to develop and commercialize its presbyopia drug VIZZ (LNZ100) in Greater China.

    Source:

  • Jun 8, 2026, 00:55 UTC

    Everest Medicines entered into an Asset Purchase Agreement with Corxel Pharmaceuticals to acquire the rights to develop, manufacture, and commercialize LNZ100 in Greater China.

    Source:

  • Jun 4, 2026, 04:00 UTC

    Everest Medicines entered into an exclusive licensing and collaboration agreement with Travere Therapeutics for civorebrutinib, a BTK inhibitor for rare kidney diseases.

    Source:

  • Jun 2, 2026, 00:00 UTC

    Travere Therapeutics entered into a license and collaboration agreement with Everest Medicines to develop and commercialize civorebrutinib (EVER001) outside China and select East and Southeast Asia.

    Source: